Navigation Links
TCF Fellow Maggie Mahar to Blog Live from Business and National Health Care Reform Conference
Date:9/13/2007

Sponsored by The Century Foundation with support from The Commonwealth Fund, and AARP

NEW YORK, Sept. 13 /PRNewswire-USNewswire/ -- The following release is being issued by The Century Foundation:

WHAT: Blogging Live from "Business and National Health Care

Reform" Conference

TCF Fellow Maggie Mahar, author of Money-Driven Medicine:

The Real Reason Health Care Costs So Much (Harper/Collins

2006) and a former financial journalists who wrote for

Insitutional Investor, the New York Times, and Barrons,

will blog live from this conference, in which CEOs of major

companies, health benefits leaders, and experts in health

care policy will discuss the renewed interest of private

sector in health care reform, the challenges to -- and

prospects for -- continued employer-based coverage, and

the strengths and weaknesses, from a business perspective,

of recent proposals for universal coverage.

WHEN: September 14th, 2007, 8:30 a.m. - 2:30 p.m.

WHERE: Read the Blog at http://www.healthbeatblog.org or

http://www.tcf.org

The event will take place at the National Press Club,

14th and F Streets, N.W., Washington, D.C.

TOPICS: The future of employment-based health insurance, the

business case for national health care reform, and

employer innovations in health care

SPEAKERS

INCLUDE: John Arensmeyer, Founder and CEO, Small Business Majority

Bruce Bodaken, CEO, Blue Shield of California

Francois de Brantes, National Coordinator, Bridges to

Excellence'/>"/>

SOURCE The Century Foundation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Developer Of Vaccine For Cancer Granted A Prestigious Fellowship
2. Schizophrenia Fellowship To Deliver Mental Health Program
3. Six Indians Win Australian Studies Fellowships
4. Gay Gang in Netherlands Lures, Rapes and Infects Fellow Homosexuals With HIV/AIDS
5. Maggie Daley to Undergo a Surgery Biopsy to Remove a Tumor from Her Breast
6. Doctors strike called off in Maharashtra
7. HIV/AIDS Declining In Maharashtra, TN, Ktk And AP: UN Report
8. Experts Warn of Bird Flu Recurrence in Maharashtra
9. Maharashtra Medical And Dental Colleges Decide To Fix Own Fees
10. Reports Of Chikun Guniya In Few Maharashtra Districts
11. Seven Dead in Maharashtra Due to Suspected Chikungunya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 Healthcare Trust of America, Inc. ("HTA"), ... execution of a purchase and sale agreement to acquire ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... subject to the satisfaction of a number of conditions. ...
(Date:12/4/2009)... Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... AGN ) as its February 2010 "Stock to Study" and ... as its February 2010 "Undervalued Stock" for investors, informational and ... opportunities involving its flagship drug Botox and other products as ...
(Date:12/4/2009)... 4 While Congress debates whether health care ... members point to 45 hospitals that lead through ... the nation while attaining the highest levels of ... hospitals have been named 2009 Leapfrog Top Hospitals, ...
(Date:12/4/2009)... recurrence is a risk for some pediatric cancers, particularly ... according to a new study published online December 4 ... . , This study was undertaken because there is ... up to 20 years) for pediatric cancer patients. , ...
(Date:12/4/2009)... Working with mice, scientists at Johns Hopkins publishing in the ... protein made by a gene called "Twist" may be the ... drive aggressive, metastatic breast cancer from other breast cancer cells. ... a relatively rare subgroup of stem cells in breast tumors ...
Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
... 31 HearAtLast Inc. (Pink,Sheets: HRAL) announced today that ... AXP ) and Wal-Mart Stores (NYSE: WMT ... a special American Express Giftcard,promotion. Starting November 15, 2007, ... they purchase a hearing aid with,their American Express card. ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... therapeutics for,the treatment of cancer, today announced that Paul ... at the 2007 Acumen BioFin Rodman &,Renshaw Conference in ... at 8:50 a.m. (Eastern) on,Tuesday, November 6, 2007. There ...
... ... Margins Exceed 70 Percent, IRVINE, Calif., Oct. 31 ... focused on the,development of minimally invasive technologies for tissue and ... increased gross margins resulted in a reduction,in operating loss in ...
... Switzerland, Oct. 31 Ipsen,(Euronext: FR0010259150; IPN) ... development specialist in oncology and,serious medical conditions ... Ipsen exclusively in-licenses know-how and new patent,applications ... in the world excluding North America, and ...
... WOODCLIFF LAKE, N.J., Oct. 30 Barr,Pharmaceuticals, Inc. ... subsidiary, Barr,Laboratories, Inc., has received tentative approval from ... generic version of Boehringer Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) (Pramipexole ... Company believes that it is the,first to file ...
... DIEGO, Oct. 30 BioMed Realty Trust, Inc.,(NYSE: ... its third quarter,ended September 30, 2007 after the market ... President and Chief Executive Officer, and Kent Griffin,Chief Financial ... Pacific Time on Thursday, November 8, 2007 to discuss ...
Other Medicine News:Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 2Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 3Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 4Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 5Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 6Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 7Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 8Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 9Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 2Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 3Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 4Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 5Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 6Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 2Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 4Health News:BioMed Realty Trust to Report 2007 Third Quarter Results 2
(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...
(Date:12/4/2009)... N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed ... Food and Drug Administration seeking approval to market its ... patent owned by Takeda Pharmaceutical Company Limited. Watson,s ...
(Date:12/4/2009)... BETHESDA, Md., Dec. 4 Drs. Neal Shore and ... recurrence from the additional analysis of secondary end points ... study of FIRMAGON® (monthly degarelix for injection) or monthly ... of treatment. Prostate cancer patients who received FIRMAGON ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 1NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 2NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 3NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 4Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 1Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 2Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 3Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 4New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 4683 1New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 4683 2
... a fully automated, upgradeable platform that ... analyzer along with a customer care ... to focus on patient care. ... are essential to efficient blood gas ...
... Agitators feature sturdy, one-piece ... texture coating and provide ... your platelets. Helmer agitators ... used in Helmer incubators ...
... platelet agitators offer a wide range of ... the drawer storage platform to agitate smoothly, ... wear down and squeak. Sturdy, one-piece perforated ... air circulation for your platelets., ,i.Series platelet ...
Platelet agitator....
Medicine Products: